Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc (NY: CYBN )

9.990 -0.040 (-0.40%)
Official Closing Price Updated: 8:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
38 39 Next >
Cybin (NEO: CYBN) (NYSE American: CYBN) Pipeline Program Receives Key Patent Approval
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Psychedelic Stock Gainers And Losers From April 18, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 14.66% at $0.28 
Via Benzinga
Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Featured in Latest Power Play Release
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Featured in Latest Power Play Release
Via Investor Brand Network
Psychedelic Stock Gainers And Losers From April 14, 2022
GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 2.50% at $5.32 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Featured in Latest Power Play Release
Via Investor Brand Network
Psychedelic Stock Gainers And Losers From April 13, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 19.41% at $0.24 
Via Benzinga
Cybin's (NYSE American: CYBN) (NEO: CYBN) CYB004 Demonstrates Advantages in Study
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Cybin’s (NYSE American: CYBN) (NEO: CYBN) CYB004 Demonstrates Advantages in Study
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB004 Demonstrates Significant Advantages over IV and Inhaled DMT in Pharmacokinetic Study
Via Investor Brand Network
Cybin's CYB0004 Shows Positive Preclinical Results Over Traditional Psychedelics
CYB004 is one of Cybin’s (NYSE: CYBN) proprietary second-generation psychedelics, developed to treat depression, anxiety, and ... 
Via Benzinga
Why Psychedelics Could Soon Replace Antidepressants
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 13, 2022 – Anxiety disorders are the most common mental illness in the US, affecting approximately 40 million adults... 
Via FinancialNewsMedia
Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT
From Cybin Inc.
Via Business Wire
Psychedelic Stock Gainers And Losers From April 11, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 4.52% at $0.17 
Via Benzinga
Performance Comparisons Of The 5 Cannabis Sector Categories
Here is a summary of how each of the 5 categories in the cannabis sector performed over four time periods, to highlight the different category trends that are underway. 
Via Talk Markets
Revive Therapeutics, Cybin Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 14.54% at $0.16 
Via Benzinga
WIPO Publishes Cybin's Patent Application For Inhaled Psychedelics Therapies
Cybin Inc. (NYSE: CYBN) announced that the World Intellectual Property Organization (WIPO) published an international patent ... 
Via Benzinga
Cybin (NYSE American: CYBN) (NEO: CYBN) Strengthens IP Position Of Psychedelic Programs
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.   
Via Benzinga
Cybin (NYSE American: CYBN) (NEO: CYBN) Strengthens IP Position of Psychedelic Programs
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Further Strengthens Long-Term IP Position of Psychedelic-Based Programs
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Strengthening Foothold in Multibillion-Dollar Mental Health Space
Via Investor Brand Network
Cybin Announces Publication of International PCT Patent Application for Inhalation Delivery of Multiple Psychedelic Molecules
From Cybin Inc.
Via Business Wire
Revive Therapeutics, Field Trip Health Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 14.48% at $0.14 
Via Benzinga
Cybi (NEO: CYBN) (NYSE American: CYBN) To Participate In Benzinga Psychedelics Conference
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Cybi (NEO: CYBN) (NYSE American: CYBN) to Participate in Benzinga Psychedelics Conference
Via Investor Brand Network
Intelgenx Technologies, Field Trip Health Among Top Psychedelic Movers Of Today
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 4.78% at $19.73 LOSERS: 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Participate in Upcoming Benzinga Psychedelics Capital Conference
Via Investor Brand Network
A Builder From The Ground Up, Doug Drysdale, CEO of Cybin: Meet Our Speakers
From his beginnings at DuPont Merck to his current position as Cybin’s (NYSE: CYBN) CEO, Doug Drysdale has certainly had an ... 
Via Benzinga
Psyched: Atai, MindMed, Enveric and Mydecine Release 2021 Earnings, Bienstar Expands To Brazil & More!
It’s earnings week in the psychedelics space, opening a new window into the financial situations of many companies in the sector. 
Via Benzinga
Cybin to Present at the Benzinga Psychedelics Capital Conference in Miami on April 19, 2022
From Cybin Inc.
Via Business Wire
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
38 39 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.